|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1B
|
|
pubmed:dateCreated |
2003-4-8
|
|
pubmed:abstractText |
A combination of irinotecan (CPT-11) and cisplatin (CDDP) was shown to be effective for extensive-disease small-cell lung cancer (ED-SCLC). To take maximum advantage of the synergistic effect between CPT-11 and CDDP, we designed a fractionated administration schedule.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:FujiwaraKeiichiK,
pubmed-author:HaradaMineM,
pubmed-author:HirakiAkioA,
pubmed-author:HirakiShunkichiS,
pubmed-author:KameiHaruhitoH,
pubmed-author:KiuraKatsuyukiK,
pubmed-author:SegawaYoshihikoY,
pubmed-author:ShibayamaTakuoT,
pubmed-author:TabataMasahiroM,
pubmed-author:TakigawaNagioN,
pubmed-author:TanimotoMitsuneM,
pubmed-author:UeokaHiroshiH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
557-60
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12680145-Adult,
pubmed-meshheading:12680145-Aged,
pubmed-meshheading:12680145-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12680145-Camptothecin,
pubmed-meshheading:12680145-Carcinoma, Small Cell,
pubmed-meshheading:12680145-Cisplatin,
pubmed-meshheading:12680145-Drug Administration Schedule,
pubmed-meshheading:12680145-Drug Synergism,
pubmed-meshheading:12680145-Female,
pubmed-meshheading:12680145-Humans,
pubmed-meshheading:12680145-Lung Neoplasms,
pubmed-meshheading:12680145-Male,
pubmed-meshheading:12680145-Middle Aged
|
|
pubmed:articleTitle |
Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.
|
|
pubmed:affiliation |
Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama 700-8558, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
